166 related articles for article (PubMed ID: 11181938)
1. Enhancement of paclitaxel delivery to solid tumors by apoptosis-inducing pretreatment: effect of treatment schedule.
Jang SH; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2001 Mar; 296(3):1035-42. PubMed ID: 11181938
[TBL] [Abstract][Full Text] [Related]
2. Determinants of paclitaxel penetration and accumulation in human solid tumor.
Kuh HJ; Jang SH; Wientjes MG; Weaver JR; Au JL
J Pharmacol Exp Ther; 1999 Aug; 290(2):871-80. PubMed ID: 10411604
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention.
Au JL; Li D; Gan Y; Gao X; Johnson AL; Johnston J; Millenbaugh NJ; Jang SH; Kuh HJ; Chen CT; Wientjes MG
Cancer Res; 1998 May; 58(10):2141-8. PubMed ID: 9605758
[TBL] [Abstract][Full Text] [Related]
4. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis.
Hershberger PA; Yu WD; Modzelewski RA; Rueger RM; Johnson CS; Trump DL
Clin Cancer Res; 2001 Apr; 7(4):1043-51. PubMed ID: 11309356
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel nanoparticle inhibits growth of ovarian cancer xenografts and enhances lymphatic targeting.
Lu H; Li B; Kang Y; Jiang W; Huang Q; Chen Q; Li L; Xu C
Cancer Chemother Pharmacol; 2007 Feb; 59(2):175-81. PubMed ID: 16718469
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous targeting of telomeres and telomerase as a cancer therapeutic approach.
Mo Y; Gan Y; Song S; Johnston J; Xiao X; Wientjes MG; Au JL
Cancer Res; 2003 Feb; 63(3):579-85. PubMed ID: 12566299
[TBL] [Abstract][Full Text] [Related]
7. Enhanced paclitaxel cytotoxicity and prolonged animal survival rate by a nonviral-mediated systemic delivery of E1A gene in orthotopic xenograft human breast cancer.
Liao Y; Zou YY; Xia WY; Hung MC
Cancer Gene Ther; 2004 Sep; 11(9):594-602. PubMed ID: 15272313
[TBL] [Abstract][Full Text] [Related]
8. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases.
Song S; Wientjes MG; Walsh C; Au JL
Cancer Res; 2001 Aug; 61(16):6145-50. PubMed ID: 11507065
[TBL] [Abstract][Full Text] [Related]
9. Different effect of paclitaxel on primary tumor mass, tumor cell contents, and metastases for four experimental human prostate tumors expressing luciferase.
El Hilali N; Rubio N; Blanco J
Clin Cancer Res; 2005 Feb; 11(3):1253-8. PubMed ID: 15709196
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley MO; Webb NL; Anthony FH; Devanesan P; Witman PA; Hemamalini S; Chander MC; Baker SD; He L; Horwitz SB; Swindell CS
Clin Cancer Res; 2001 Oct; 7(10):3229-38. PubMed ID: 11595719
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.
Safavy A; Bonner JA; Waksal HW; Buchsbaum DJ; Gillespie GY; Khazaeli MB; Arani R; Chen DT; Carpenter M; Raisch KP
Bioconjug Chem; 2003; 14(2):302-10. PubMed ID: 12643740
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic advantage from combining paclitaxel with the hypoxia-selective cytotoxin NLCQ-1 in murine tumor- or human xenograft-bearing mice.
Papadopoulou MV; Ji M; Ji X; Bloomer WD; Hollingshead MG
Cancer Chemother Pharmacol; 2002 Dec; 50(6):501-8. PubMed ID: 12451478
[TBL] [Abstract][Full Text] [Related]
13. Complete regression of well-established tumors using a novel water-soluble poly(L-glutamic acid)-paclitaxel conjugate.
Li C; Yu DF; Newman RA; Cabral F; Stephens LC; Hunter N; Milas L; Wallace S
Cancer Res; 1998 Jun; 58(11):2404-9. PubMed ID: 9622081
[TBL] [Abstract][Full Text] [Related]
14. Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents.
Kurtzberg LS; Roth SD; Bagley RG; Rouleau C; Yao M; Crawford JL; Krumbholz RD; Schmid SM; Teicher BA
Cancer Chemother Pharmacol; 2009 Oct; 64(5):1029-38. PubMed ID: 19277662
[TBL] [Abstract][Full Text] [Related]
15. Transferrin coupled vesicular system for intracellular drug delivery for the treatment of cancer: development and characterization.
Vaidya B; Vyas SP
J Drug Target; 2012 May; 20(4):372-80. PubMed ID: 22339366
[TBL] [Abstract][Full Text] [Related]
16. Tumor priming enhances delivery and efficacy of nanomedicines.
Lu D; Wientjes MG; Lu Z; Au JL
J Pharmacol Exp Ther; 2007 Jul; 322(1):80-8. PubMed ID: 17420296
[TBL] [Abstract][Full Text] [Related]
17. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
18. Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Leggas M; Stewart CF; Woo MH; Fouladi M; Cheshire PJ; Peterson JK; Friedman HS; Billups C; Houghton PJ
Clin Cancer Res; 2002 Sep; 8(9):3000-7. PubMed ID: 12231547
[TBL] [Abstract][Full Text] [Related]
19. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
20. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]